Embargo Watch

Keeping an eye on how scientific information embargoes affect news coverage

Go read this WSJ Health Blog post on ASCO and Tasigna. It might be embargoed.

leave a comment »

Ah, ASCO.

The meeting of the American Society of Clinical Oncology that spawned an embargo break before it even got underway kicks off today, officially, in Chicago. And just in time comes a fantastic post by The Wall Street Journal’s Ron Winslow about an ASCO-related situation that my Twitter followers have already called “crazy,” “surreal,” and “head-scratchingly odd.”

These are compliments, by the way, that go along with another Twitter follower’s comment that Ron is a “genius.”

I agree, and when you read the post, you will too. I can’t possibly do it justice in a short summary, so I’ll just say that it involves Novartis’ anti-chronic myelogenous leukemia drug Tasigna, a major but un-named — for reasons you can guess — medical journal,  and ASCO. Ron is honest — tongue planted only somewhat firmly in cheek, I would guess — about the risk of “being drawn and quartered” for posting it.

So go read it. And check back here tomorrow morning for a post on another aspect of an, um, closely related subject. Let’s just say I’m not the bold genius that Ron Winslow is.

Written by Ivan Oransky

June 4, 2010 at 10:07 am

Posted in Uncategorized

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: